Potential of valsartan+sacubitril therapy in hypertensive heart disease

Potential of valsartan+sacubitril therapy in hypertensive heart disease

The course of hypertension is often complicated by left ventricular hypertrophy (or hypertensive heart disease, HHD). The main “corridor” of natural HHD is development of heart failure with preserved ejection fraction (HFpEF). With HFpEF, the bioavailability of natriuretic peptides (NP) is significa...

Full description

Bibliographic Details
Main Authors:	A. G. Ovchinnikov, A. D. Gvozdeva, A. V. Potekhina, M. V. Vitsenya, F. T. Ageev
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2021-08-01
Series:	Российский кардиологический журнал
Subjects:	natriuretic peptide neprilysin sacubitril left ventricular hypertrophy hypertensive heart disease heart failure with preserved ejection fraction
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/4568

Similar Items

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
by: Reza Mohebi, et al.
Published: (2023-04-01)

Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure
by: T. V. Ashcheulova, et al.
Published: (2019-12-01)

Combined drug sacubitril/valsartan -a new era of treatment of chronic heart failure
by: V. S. Nikiforov
Published: (2020-10-01)

The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Sharath Kommu, et al.
Published: (2024-03-01)

The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients
by: Ji‐Hye Oh, et al.
Published: (2022-08-01)

Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF
by: Yanhong Guo, et al.
Published: (2022-11-01)

Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure
by: Sheldon E. Litwin, et al.
Published: (2022-12-01)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
by: Domingo Pascual-Figal, et al.
Published: (2021-11-01)

Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction
by: Giovanni Battista Bolla, et al.
Published: (2022-05-01)

Asymptomatic Left Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort Study
by: Artem Ovchinnikov, et al.
Published: (2022-07-01)

Is Sacubitril/Valsartan Able to Change the Timing for Implantation of Cardiac Devices in Heart Failure with Reduced Ejection Fraction?
by: Marta Afonso Nogueira, et al.
Published: (2022-08-01)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
by: Giuseppe Vergaro, et al.
Published: (2021-02-01)

First signs of reverse cardiac remodeling following one-month, low dose add-on sacubitril-valsartan therapy in patients with advanced systolic heart failure
by: Wioletta Sacharczuk, et al.
Published: (2022-03-01)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
by: Senthil Selvaraj, et al.
Published: (2021-09-01)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
by: Mi‐Gil Moon, et al.
Published: (2021-06-01)

Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure
by: Klaus K. Witte, et al.
Published: (2023-02-01)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
by: Valeria Visco, et al.
Published: (2022-10-01)

EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2018-05-01)

Blood Immune Cell Alterations in Patients with Hypertensive Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction
by: Artem Ovchinnikov, et al.
Published: (2023-07-01)

Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure
by: Diana-Carina Iovanovici, et al.
Published: (2022-09-01)

Clinical efficacy of sacubitril/valsartan in treatment of acute STEMI complicated with HFpEF
by: Kong Can, Peng Hui
Published: (2023-06-01)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
by: Lars H. Lund, et al.
Published: (2022-02-01)

Effect of sacubitril valsartan on heart failure with mid-range or preserved ejection fraction in patients on maintenance hemodialysis: real-world experience in a single-center, prospective study
by: Xiao-mei Huang, et al.
Published: (2024-01-01)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
by: Muhammad Nauman Khan, et al.
Published: (2023-03-01)

Benefits of sacubitril/valsartan use in patients with chronic heart failure after cardiac valve surgery: a single-center retrospective study
by: Jian Zheng, et al.
Published: (2023-04-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
by: Katie L. Peppin, et al.
Published: (2020-01-01)

The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
by: Yu Xu, et al.
Published: (2023-05-01)

Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
by: Juan Carlos López‐Azor, et al.
Published: (2019-12-01)

Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
by: Sha Fu, et al.
Published: (2021-06-01)

Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease—A Real-World Experience
by: Sara C. Pereira, et al.
Published: (2023-02-01)

Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study
by: Giuseppe Armentaro, et al.
Published: (2021-08-01)

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
by: Cong Zhao, et al.
Published: (2022-11-01)

Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction – “ARNI-PRESERVED” study
by: Pankaj Jariwala, et al.
Published: (2021-01-01)

Effects of sacubitril/valsartan in patients with cancer therapy-related heart failure
by: Marina V. Vitsenya, et al.
Published: (2023-09-01)

Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits
by: Yu Chun, et al.
Published: (2021-09-01)

Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)
by: Andrea Di Lenarda, et al.
Published: (2023-01-01)

Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats
by: Wenchao Zhang, et al.
Published: (2021-01-01)

Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction
by: Jeffrey S. Tran, et al.
Published: (2021-04-01)

Add-on Sacubitril/Valsartan Therapy Induces Left Ventricular Remodeling in Non-responders to Cardiac Resynchronization Therapy to a Similar Extent as in Heart Failure Patients Without Resynchronization
by: Krisztina Mária Szabó, et al.
Published: (2024-01-01)